Table 3 On-treatment virologic response for all patients (ITT population)
n/N (%) | Phase 2/3 group (N = 125) | Phase 1 group (N = 16) |
|---|---|---|
Week 2 | ||
<25 IU/ml undetectable | 30/125 (24.0) | 1/15 (6.7) |
<25 IU/ml undetectable/detectable | 99/125 (79.2) | 5/15 (33.3) |
Week 4 | ||
<25 IU/ml undetectable (RVR) | 90/125 (72.0) | 7/15 (46.7) |
<25 IU/ml undetectable/detectable | 112/125 (89.6) | 15/15 (100.0) |
Week 12 | ||
<25 IU/ml undetectable (cEVR) | 108/114 (94.7) | 13/15 (86.7) |
<25 IU/ml undetectable/detectable | 113/114 (99.1) | 14/15 (93.3) |
Week 24 | ||
<25 IU/ml undetectable | 102/105 (97.1) | 12/13 (92.3) |
<25 IU/ml undetectable/detectable | 104/105 (99.0) | 13/13 (100.0) |
Week 36 | ||
<25 IU/ml undetectable | 38/44 (86.4) | 10/11 (90.9) |
<25 IU/ml undetectable/detectable | 41/44 (93.2) | 11/11 (100.0) |
Week 48 | ||
<25 IU/ml undetectable | 36/39 (92.3) | 9/9 (100.0) |
<25 IU/ml undetectable/detectable | 37/39 (94.9) | 9/9 (100.0) |
EOT | ||
<25 IU/ml undetectable (EOTR) | 105/125 (84.0) | 13/15 (86.7) |
<25 IU/ml undetectable/detectable | 109/125 (87.2) | 14/15 (93.3) |